Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

R), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint. Importantly, the trial also confirmed the positive results seen in the first Phase III trial with microplasmin. The results of the second Phase III trial (TG-MV-007) were presented for the first time at the American Society of Retina Specialists (ASRS) Annual Meeting by Dr. J. Michael Jumper (West Coast Retina and Medical Group and California Pacific Medical Center, California, USA). The trial recruited 326 patients at 48 centers in Europe and the U.S.

The detailed positive results from the first Phase III trial in the microplasmin MIVI-TRUST program (TG-MV-006) were presented at the World Ophthalmology Congress in Berlin in June 2010. The pooled results of both trials will be presented at the upcoming EURETINA (European Society of Retina Specialists) Congress in Paris, France, on September 4 by Prof. Peter Stalmans (University Hospitals Leuven, Belgium).

In his presentation at ASRS, Dr. Jumper highlighted that the TG-MV-007 study had met its primary endpoint, with 25.3% of the 245 microplasmin treated patients achieving resolution of their VMA at 28 days, compared to 6.2% of the 81 patients who received a placebo injection, a highly statistically significant result (p=0.001). In patients without epiretinal membrane, microplasmin was shown to be even more effective with 34.5% of patients seeing resolution of their VMA at 28 days, compared to 6.4% of placebo treated patients. Epiretinal membrane is a layer of scar tissue which builds up on the macula, making it more difficult to achieve resolution of VMA without surgical intervention. Epiretinal membrane can be easily identified using Optical Coherence Tomography (OCT).


'/>"/>
SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 03, 2015 CIRTEC Medical Systems ... services for complex Class III implantable devices and minimally ... UT Dallas-led initiative aimed at identifying potentially marketable biomedical ... institutions and moving them more efficiently from the laboratory ... history of working with the world's largest OEMs and ...
(Date:6/3/2015)... and CHICAGO , June 3, 2015 ... "the Company"; LSE: CIR), a specialty biopharmaceutical company focused ... relating to the Company,s novel immunotherapy candidates targeting house ... at the 2015 European Academy of Allergy and Clinical ... Spain on 6-10 June. Sunday, ...
(Date:6/3/2015)... Milan, Tennessee (PRWEB) June 03, 2015 ... facility in Milan, Tennessee to support the RCBC Waste ... Energy is fourth generation in the family business, ... since 1908. His family added recycling to their ... waste and recycling services to the Fortune 500 companies ...
(Date:6/3/2015)... Roanoke, Virginia (PRWEB) June 03, 2015 ... officially changed its name to PogoTec™, Inc. ( ... of its electronic wearable device products and technologies it ... the creation of three business divisions, PogoTec™ will provide ... wearable devices as follows: , , ...
Breaking Biology Technology:CIRTEC Medical Systems to support new UT Dallas-led Initiative to deliver biomedical technologies from laboratory bench to bedside more efficiently 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 3Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3
... Pharsight,Corporation (Nasdaq: PHST ), a leading provider ... clinical drug,development announced today that it will be ... Conference on February 28, 2008 at the,Walt Disney ... and CEO, and William Frederick, Senior Vice President ...
... QED International Associates, Inc.,administrator for the HealthShares(TM) Indexes, ... Exchange-Traded Funds, today announced,that effective at the opening ... Co. (NYSE: KV.A) will replace Bradley Pharmaceuticals, Inc.,(NYSE: ... Wound Care Index.,Bradley is being acquired by Nycomed ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced its financial ... For the quarter, the company reported a net,loss of ... a net loss,of $6.9 million, or $0.53 per common ... shares outstanding on January 31, 2008 and 2007 were,34,971,087 ...
Cached Biology Technology:Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference 2Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7
(Date:5/5/2015)... OXFORD, Conn. , May 5, 2015, NXT-ID, ... biometric authentication company focused on the growing mobile commerce market, ... the Company,s Chief Technology Officer, is presenting  at CARTES SECURE ... May 5-7, 2015. The three-day conference ... session David is speaking in is themed Global Fraud: ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
(Date:4/20/2015)... DUBAI , April 20, 2015 ... soars   Glenbeigh Records Management (GRM), ... contract with Dubai Islamic Bank. Having built up an impressive ... is now a leading player within the records management sector ... company expects to double is GCC staffbase and employ a ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... Science Research Conference focuses on signaling pathway feedback loops, ... rewiring. A growing appreciation has emerged that though ... been identified in the last three decades an in ... inputs needs to be elucidated. The conference ...
... Every picture tells a story, but the story ... change could be incomplete, according to new research. ... have shown that the peak in forest greenness as ... direct measures of peak chlorophyll content in leaves, which ...
... the winners of its annual CPOW Travel Awards to ... Moscone Center in San Francisco, February 15-19, 2014. CPOW, ... has initiated these travel fellowships to increase the number ... Meeting. The recipients of this competitive award must ...
Cached Biology News:Image or reality? Leaf research needs photos and lab analysis 2Image or reality? Leaf research needs photos and lab analysis 3Biophysical Society announces winners of 2014 CPOW Travel Awards 2